drugset / Trial / NCT05641311

Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants

NCT05641311

Phase 1 Completed 24 enrolled Alexion Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of the study is to confirm how long ALXN1840 stays in the body of Japanese and non-Japanese healthy participants (that is, pharmacokinetic \[PK\] profile).

Timeline

Start
2019-02-20
Primary completion
2019-05-02
Completion
2019-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject TIOMOLIBDATE CHOLINE Small molecule 15 mg Oral
Subject TIOMOLIBDATE CHOLINE Small molecule 60 mg Oral

Indications